Human, Rat, Mouse, Porcine, Ovine VIP ELISA Kit

Irradiation has been regarded as a perspective preservation technology to prolong the shelf life of goat meat. In order to evaluate the effect of irradiation on goat meat, the high-throughput proteomics was applied to observe the proteome profiles changes and off-flavor formation of irradiated goat meat. A total of 207 proteins with significant changes (fold change > 2 or < 0.5, P < 0.05, VIP > 1) was determined in five irradiation doses (0, 1, 2, 4 and 6 kGy). Among them, 26 proteins involving 7 functional enrichments terms were found to be related to off-flavor. Particularly, proteins involved in protein oxidation, cysteine and methionine metabolism lead to irradiation off-flavor formation. However, the irradiation off-flavor will gradually dissipate due to metabolic process during storage. This study was designed to provide a proteomic insight into irradiation off-flavor of goat meat and suggest an underlying connection between off-flavor formation and biological processes.

To systematically evaluate the efficacy and safety of oxetam in the treatment of vascular cognitive dysfunction and the feasibility of an Au/polypropionic acid Nanometer drug delivery system to provide evidence for clinical application. PubMed, Shanghai embase, Cochrane Library, CNKI, VIP information, and Wanfang database were searched from the establishment of the database to April 2018. Patients were divided into two groups according to whether they received olacetam: the experimental group and the control group. In addition, the control group was divided into the placebo control group and the positive control group according to whether the control group received a placebo or other medication treatment controls. In the control group, a meta-analysis, a publication bias assessment, and sensitivity analysis were performed with Revman 5.3 and Stata 14.0. The results of the meta-analysis showed that compared with placebo and other medications, oxiracetam significantly improved the mental status of patients, Concise Mental State Checklist score [mean difference (MD) = 5.29, P < 0.01] and Montreal Cognitive Assessment score (MD = 4.32, P < 0.01). The Barthel Index demonstrated that oxiracetam significantly improved the quality of the daily life of patients (MD = 18, P < 0.01), but there was no difference between olacetam and placebo or other medications in the rating of activities of daily living (ADLs). The total effective rate of olacetam was significantly higher than that of other treatments (P < 0.01). Compared with placebo and other medications, the safety of oxiracetam was not significantly different (P> 0.05). Based on the current clinical evidence, olacetam is more effective and safer than alternatives in the treatment of vascular cognitive dysfunction.